At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 344 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
In Brief
A Phase 3 clinical trial evaluating adalimumab and placebo for Ankylosing Spondylitis. Completed, enrolled 344 participants across 9 sites.
Detailed Summary
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedMay 2010
Primary CompletionSep 2010
Study CompletionFeb 2011
TodayJul 2026
First PostedMay 3, 2010
Enrollment StartJan 1, 2010
Primary CompletionSep 1, 2010
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.2 years ago
Interventions
adalimumabbiological
Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
placeboother
Prefilled syringe, matching placebo administered subcutaneously every other week